High nuclear METTL3 expression was also an independent prognostic indicator of poorer BCSS, TTDM and DFS independent of patient age, ER status, LVI, nodal stage, tumour grade and size in both the whole cohort and the TNBC sub-cohort. This evidence concerns the gene METTL3 and neoplasm.